Member Info for Fruitsnveg

Interesting. Thank you.

The Palladin,
I hope you don't mind but I have to ask; are you named after the protein, the mutation, the bridge or the spy novel?

Docdaneeka, 20 years is not really a long time in drug development, and certainly wouldn't be the longest. It's interesting to note that Mulnupiravir was developed at Emory University (and subsequently abandoned) about a decade before it was bought by Ridgeback, who then partnered with Merck to develop it further. Ridgeback Therapeutics were essentially a husband and wife founded-company, much smaller than Synairgen. Also interesting is that Ridgeback licenced the drug, the company was not taken over - so any profits from the collaboration are split between Ridgeback and Merck equally. I guess this shows us that where there is a will, there is a way.....

Aether
"This company has made serious mistakes that a larger and better resourced company wouldn't have."
The fact is, big pharma, for ALL their billions and expertise have had drugs fail many trials. I can't think of any that have not - can you? I think your statement is a grossly inaccurate when considered in it's fullest context. If it were true, every drug the big boys try to get to market would make it, yet sadly, very few do.

Personally I think there could be news pre-AGM. It would make a lot of sense for the BOD to offer a 'sweetner' before the subject of options are broached at the AGM (albeit exercisable in 3 yrs and only when certain performance-related conditions are met, a proposal that did elicit some ire here). Releasing positive news at the right time would be greasing those wheels and ensuring a more palatable outcome. That is how I would play it at least, if I was the BOD.

Interesting that "BA.5 developed more in the lungs and less in the throat".
Thanks for posting Nessab.

Axe I suggest you read the Financial report dd 6th June, that should answer most if not all of your questions. I don't believe the company ever made any 'promises' to investors, as you state. They have however expanded their risk section in this years report, so do have a good read of that, I would not like to think anyone feels misled by their continued investment here. To reiterate, the options are exercisable in 3 years and are NOT guaranteed. Probably because by that time (if not well before!) the company should have achieved a commercial income stream be it via TO, licencing or another route. If you feel passionate enough about it, vote at the AGM. If not, you are free to sell, no one is stopping you.
One last thought - If the future was indeed as bleak as you seem to think it is under such rank incompetent mis-mangement, you should ask yourself why the the company would postpone options for 3 years? IMHO, to even consider these new options, at this point in time, under the current cloud that is a failed P3, I think they company must feel some level of optimism ahead. Otherwise why propose these options now? Just my own thought on the matter.... nothing I say should be taken as investment advice obvs / DYOR.

No, I don’t. I expect a well run company to have an equivalent long term incentive plan. 3 years is light years away. And, there is NO guarantee they get them in 3 years. They must perform per page 26 of the report - there are conditions attached!! It’s basically a tax efficient way of paying staff. There’s no free lunch here. You can vote against it if you don’t like it. Or you can sell your shares if still not happy. Personally I see it as a non-event.

Per the Financial Report, the options don't get exercised for another 3 years, and even then they have to meet performance conditions. They are not guaranteed. It's a long term incentive not a short-term lifestyle vehicle. Read the report.

Matt,

That summit was in 2021 (as was her tweet - June 2021, not June 2022). It's a year old.

A mention for Synairgen alongside other Asthma treatment heavyweights - see last para: https://www.labiotech.eu/trends-news/upstream-asthma/.

Reassuring to note SNG001 is referenced in the general respiratory space (apart from Covid). As an investor that is important to me that SNG001 has such potentially wide use, above and beyond the current pandemic. The figures quoted in relation to the asthma market are massive. As we already knew, but worth remembering, SNG001 is not dependent on one route to market.

"Another trial due to start in Q4 2022, finish recruiting in Q3 2023, with results due H2 2024".
I missed that one. Such a trial and timeframe - was that quoted by the company?

Well observed Skippy. "Any potential partners might say - let's see what the Activ2 data says first...." By keeping A2 results out of public domain for just a bit longer (so it can be assessed alongside P3 deep dive data presented at ATS this week), the Americans are keeping their place at the top of the queue. Clever move, and who can blame them, they paid for A2 after all. They will be looking at the bigger picture. I expect we will have a much better idea of future steps after that process is concluded.

An NIH-funded trial doesn't require a boardroom shuffle. One is not contingent on the other.
The only people I see benefitting from short-term agitation are those who it best serves -> short -term punters and P&D merchants. The board is awash with both, has been since H2 2020. I expect they'll retreat under their rocks after the AGM, the usual howl and scowl crew.

Agree. Like observation that their niche market is the late Gen Z, who are least affected by the cost of living crisis. No mortgages, no rent to pay. Tat market won't fall away when they are getting what they want.

Docdaneeka, likewise hope you are well too. I'm quietly very optimistic now that the deep dive on the data has been presented by the experts to the experts. The findings read very positive for me. I see a commercial path for this (100%) and I don't take the pessimistic view that it will take 5 years. or anywhere near that. People forget too easily how MUCH path-laying manufacturing work was done prior to Feb 2022. There's too much commercial upside (in terms of savings on sky-high costs of global critical care beds and resources) for the drug to not be put through a final lap. To ignore the science and not take forward what so obviously shows promise would be a colossal waste of 15 years development. It would be an insane bet against the gains made in understanding of Covid in the past 2 years. I don't think the powers that be (certainly in the US) are stupid enough to walk away from a drug that could meet a key need of the most vulnerable patients in hospital. With or without Covid. The savings of that alone sits, I'm guessing, somewhere in the billions? Critical care does not come cheap. The question in my mind is now - who moves first. Personally, I think there will be interesting conversations out of ATS. I remain very hopeful for the company.

Good morning Docdaneeka,
"Scientific Integrity" is the cornerstone of events like ATS 2022. No commercial activity will take place in Auditoriums, it's centred on sharing of info amongst the scientific community. Session speaker instructions for ATS 2022 are clear : "Content must provide objective information based on scientific methods generally accepted in the medical community and be free of commercial bias". I would assume horse-trading can be done at the bar later, or some other more social commercial space, once findings are presented. It is the right thing for Synairgen scientists to have taken the floor, RM's role, along with other CEO's, is in the background at ATS. If it was a beauty parade or a non-scientific event, the CEO would play a higher-vis role. But the fact that we don't see him doesn't mean he isn't there doing the walk and talk.

-> vox markets podcast dd 13th May.
Worth a listen.

Good move to check out yourself, always the best way to approach an investment like this.
Here's a recent recording from Wallingham.
https://www.**********.co.uk/articles/sarah-willingham-of-nightcap-discusses-their-impressive-growth-and-expanding-pipeline-c558abf/

So, what you're saying Woodstock, is that Polygon are buying junk stock at ten times its value for no apparent reason? Perhaps it's simply boredom that keeps them buying here at much elevated prices, not the 3p you seem to wish we would all believe it's worth? What fools our II's must be?!

To think that our largest investor and their team of professional advisors have miscalculated their investment to such a laughable extent that they are simply throwing 10 times the stocks worth (their shareholders cash) into a black hole of junk, with no apparent plan to return value here???? You think we should believe this?

Tsk, tsk. I know you are smarter than that.